Announcements

Announcements

Paul G. Allen Frontiers Group [to 13 Apr 2019]
https://www.alleninstitute.org/news-press/
No new digest content identified.

BMGF – Gates Foundation [to 13 Apr 2019]
http://www.gatesfoundation.org/Media-Center/Press-Releases
No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 13 Apr 2019]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

CARB-X [to 13 Apr 2019]
https://carb-x.org/
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 13 Apr 2019]
http://cepi.net/
No new digest content identified.

Clinton Health Access Initiative, Inc. (CHAI) [to 13 Apr 2019]
https://clintonhealthaccess.org/about/
No new digest content identified.

EDCTP [to 13 Apr 2019]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.

Emory Vaccine Center [to 13 Apr 2019]
http://www.vaccines.emory.edu/
No new digest content identified.

European Medicines Agency [to 13 Apr 2019]
http://www.ema.europa.eu/ema/
News and press releases
No new digest content identified.

European Vaccine Initiative [to 13 Apr 2019]
http://www.euvaccine.eu/news-events
Latest news
New Project Manager vacancy at EVI
10 April 2019
EVI has an exciting new Project Manager position. Deadline for applications: 6th May 2019, 17:00 CET.

FDA [to 13 Apr 2019]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
No new digest content identified.

Fondation Merieux [to 13 Apr 2019]
http://www.fondation-merieux.org/
No new digest content identified.

Gavi [to 13 Apr 2019]
https://www.gavi.org/https://www.gavi.org/https://www.gavi.org/
Latest News
No new digest content identified.

GHIT Fund [to 13 Apr 2019]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.

Global Fund [to 13 Apr 2019]
https://www.theglobalfund.org/en/news/
News
No new digest content identified.

Hilleman Laboratories [to 13 Apr 2019]
http://www.hillemanlabs.org/
No new digest content identified.

Human Vaccines Project [to 13 Apr 2019]
http://www.humanvaccinesproject.org/media/press-releases/
No new digest content identified.

IAVI [to 13 Apr 2019]
https://www.iavi.org/newsroom
No new digest content identified.

IFFIm
http://www.iffim.org/library/news/press-releases/
No new digest content identified.

IFRC [to 13 Apr 2019]
http://media.ifrc.org/ifrc/news/press-releases/
Selected Press Releases, Announcements
Democratic Republic of the Congo
DR Congo: “Ebola is spreading faster, and many people are no longer seeking care”
Nairobi/Geneva, 11 April 2019 –The deadly Ebola outbreak in the Democratic Republic of the Congo is worsening as trust in the response effort falters, says the International Federation of Red Cross and Red Crescent Societies.
[See DR Congo – Ebola above for details]

IVAC [to 13 Apr 2019]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
No new digest content identified.

IVI [to 13 Apr 2019]
http://www.ivi.int/
IVI News & Announcements
[Undated]
Experts find evidence of underfunding in rheumatic heart disease research
IVI’s Director General, Dr. Jerome Kim was a member of the team of experts that looked at the underfunding of rheumatic heart disease (RHD) research.
RHD, a long-term consequence of Streptococcus pyogenes (Group A streptococcus, or GAS) infection, is estimated to affect at least 33 million people globally, causing approximately 300,000 deaths yearly. Despite this huge disease burden, RHD continues to receive relatively little attention from both researchers and the global health community. This translates into little funding, which limits the opportunities for innovations in disease control.
By comparing 16 major tropical diseases, using data from the Global Burden of Disease Study and funding from the G-FINDER database, the team established that RHD is the least-funded illness relative to its disease burden. The study was published in the Transactions of The Royal Society of Tropical Medicine and Hygiene on March 30, 2019 and can be accessed at: https://doi.org/10.1093/trstmh/trz014

JEE Alliance [to 13 Apr 2019]
https://www.jeealliance.org/
Selected News and Events
No new digest content identified.

MSF/Médecins Sans Frontières [to 13 Apr 2019]
http://www.msf.org/http://www.msf.org/http://www.msf.org/
Selected News; Project Updates, Reports [as presented on website]
Press Release 12 April 2019
Humanitarian mechanism for vaccines used for first time in Europe to counter high prices
[See Milestones above for detail]

Cyclone Idai & Southern Africa flooding
From emergency to recovery: Mozambique one month after Cycl…
Project Update 12 Apr 2019

Cyclone Idai & Southern Africa flooding
Chimanimani: A community in distress after Cyclone Idai
Project Update 10 Apr 2019

Child health
“Children with chronic diseases need our attention”
Interview 9 Apr 2019

NIH [to 13 Apr 2019]
http://www.nih.gov/news-events/news-releases
Monday, April 8, 2019
Scientists review influenza vaccine research progress and opportunities
What
In a new series of articles, experts in immunology, virology, epidemiology, and vaccine development detail efforts to improve seasonal influenza vaccines and ultimately develop a universal influenza vaccine. The 15 articles are part of a supplement in the April 15 issue of the Journal of Infectious Diseases. Researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and scientists supported by NIAID, are among the contributing authors. Barney S. Graham, M.D., Ph.D., deputy director of NIAID’s Vaccine Research Center (VRC), and Michelle C. Crank, M.D., head of the Translational Sciences Core in the VRC’s Viral Pathogenesis Laboratory, edited the supplement.
Articles
Articles in the supplement from NIAID experts include:
CI Paules and AS Fauci. Influenza vaccines: good, but we can do better. Journal of Infectious Diseases DOI: 10.1093/infdis/jiy633 (2019)
CM Saad-Roy et al. Dynamic perspectives on the search for a universal influenza vaccine. Journal of Infectious Diseases DOI: 10.1093/infdis/jiz044 (2019)
DM Morens and JK Taubenberger. Making universal influenza vaccines: lessons from the 1918 pandemic. Journal of Infectious Diseases DOI: 10.1093/infdis/jiy728 (2019)
MC Crank et al. Preparing for the next influenza pandemic: the development of a universal influenza vaccine. Journal of Infectious Diseases DOI: 10.1093/infdis/jiz043 (2019)
M Kanekiyo et al. New vaccine design and delivery technologies. Journal of Infectious Diseases DOI: 10.1093/infdis/jiy745 (2019)

April 9, 2019
NIH researchers make progress toward Epstein-Barr virus vaccine
What
A research team led by scientists from NIH’s National Institute of Allergy and Infectious Diseases (NIAID) has determined how several antibodies induced by Epstein-Barr virus (EBV), a herpesvirus that causes infectious mononucleosis and is associated with certain cancers, block infection of cells grown in the laboratory. They then used this information to develop novel vaccine candidates that, in animals, elicited potent anti-EBV antibody responses that blocked infection of cell types involved in EBV-associated cancers.
Currently, there is no licensed vaccine for EBV. The virus is associated with certain cancers (nasopharyngeal and gastric) of epithelial cells, which form the lining of the body’s surfaces, as well as Burkitt and Hodgkin lymphomas, which are cancers of the immune system’s B cells. Worldwide, about 200,000 cases of EBV-associated cancers occur annually, resulting in 140,000 deaths
Article
W Bu et al. Immunization with components of the viral fusion apparatus elicits antibodies that neutralize Epstein-Barr virus in B cells and epithelial cells. Immunity DOI: 10.1016/j.immuni.2019.03.010 (2019).

PATH [to 13 Apr 2019]
https://www.path.org/media-center/https://www.path.org/media-center/https://www.path.org/media-center/
April 10, 2019 by PATH
PATH applauds reintroduction of Global Health Security Act in U.S. Congress
Washington, D.C., April 10, 2019 — PATH applauds the bipartisan reintroduction of the Global Health Security Act in the U.S. Congress by Representatives Gerry Connolly (D-VA) and Steve Chabot (R-OH). The legislation aims to reaffirm U.S. government commitments to global health security that were made in the wake of the 2014-2016 West Africa Ebola crisis. As a leading funder and technical expert in the management of infectious disease outbreaks, the U.S. government plays a vital leadership role in today’s volatile world of more frequent and severe outbreaks…

April 8, 2019 by PATH
PATH CEO to step down at end of 2019; search underway for new CEO
Seattle, WA, March 8, 2019 – PATH announced today that President and CEO Steve Davis plans to step down at the end of 2019, after more than seven years leading the organization. Mr. Davis will continue to oversee PATH until a new CEO is in place, and will support the transition as a new leader comes on board. A global search will commence today to select his successor…

Sabin Vaccine Institute [to 13 Apr 2019]
http://www.sabin.org/updates/pressreleases
No new digest content identified.

UNAIDS [to 13 Apr 2019]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
12 April 2019
Malawi launches its health situation room

11 April 2019
Scaling up stigma-free services for women in Egypt

8 April 2019
Burkina Faso piloting PrEP

8 April 2019
HIV: a heavy burden on many cities

UNICEF  [to 13 Apr 2019]
https://www.unicef.org/media/press-releases
Selected Statements, Press Releases, Reports

Statement
Nearly half a million children in Tripoli at immediate risk
Statement by Abdel-Rahman Ghandour, UNICEF Special Representative in Libya
09/04/2019

Press release
175 million children are not enrolled in pre-primary education – UNICEF
UNICEF’s first-ever global report dedicated to early childhood education highlights a lack of investment in pre-primary by the majority of governments worldwide
08/04/2019

Press release
World Bank and UNICEF partner to promote education, skills and training for young people
World Bank to invest $1 billion to boost job prospects for young people in alignment with Generation Unlimited
09/04/2019

Press release
Climate change threatens lives and futures of over 19 million children in Bangladesh
UNICEF report calls for urgent action to keep children safe and mitigate impact on vital services

Vaccine Confidence Project [to 13 Apr 2019]
http://www.vaccineconfidence.org/
Editorial
Reverse global vaccine dissent
Larson HJ, Schulz WS. 2019 SCIENCE VOL 364 ISSUE 6436

Vaccine Education Center – Children’s Hospital of Philadelphia [to 13 Apr 2019]
http://www.chop.edu/centers-programs/vaccine-education-center
Published on Apr 10, 2019
Measles Outbreaks
In this video, Dr. Offit explains who may need measles vaccines during an outbreak. The accompanying article includes what you need to know about measles disease, the vaccine that helps to prevent it, and considerations for both vaccinated and unvaccinated individuals during an outbreak.

Wellcome Trust [to 13 Apr 2019]
https://wellcome.ac.uk/news
No new digest content identified.

The Wistar Institute [to 13 Apr 2019]
https://www.wistar.org/news/press-releases
No new digest content identified.

World Organisation for Animal Health (OIE) [to 13 Apr 2019]
http://www.oie.int/en/for-the-media/press-releases/2019/http://www.oie.int/en/for-the-media/press-releases/2019/http://www.oie.int/en/for-the-media/press-releases/2019/
No new digest content identified.

::::::

BIO [to 13 Apr 2019]
https://www.bio.org/insights/press-release
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 13 Apr 2019]
http://www.dcvmn.org/
No new digest content identified.

IFPMA [to 13 Apr 2019]
http://www.ifpma.org/resources/news-releases/
No new digest content identified.

PhRMA [to 13 Apr 2019]
http://www.phrma.org/press-room
No new digest content identified.

Industry Watch [to 13 Apr 2019]
:: Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
The U.S. FDA awarded Breakthrough Therapy Designation for this potential indication based on these Phase 2 data
The Biologics License Application is expected to be submitted to the U.S. FDA by the end of 2020, subject to the successful completion of Phase 3 studies
April 13, 2019